4/A: Third Harmonic Bio Executive Granted 297,000 Stock Options, Amending Previous Filing

Christopher Dinsmore, Chief Scientific Officer of Third Harmonic Bio, received 297,000 employee stock options on May 16, 2024, according to an amended SEC Form 4 filing.

Summary

• Christopher Dinsmore, the Chief Scientific Officer of Third Harmonic Bio, Inc., was granted 297,000 employee stock options on May 16, 2024.
• The options have an exercise price of $14.23.
• 25% of the shares will vest on May 16, 2025, and the remaining shares will vest monthly until fully vested, contingent upon continued service.
• This Form 4/A amends a previous filing from May 20, 2024, to correct the number of options granted, which was initially misreported as 210,000.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to executive compensation. It's neutral in tone and doesn't indicate any significant positive or negative developments for the company.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to align the interests of management with those of shareholders and incentivize long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Third Harmonic Bio.
• Comparable companies such as BioNTech, Moderna, and Alnylam Pharmaceuticals also utilize stock options as part of their executive compensation strategy.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term value creation.

Stakeholder Impact

• The stock option grant could incentivize the Chief Scientific Officer to drive innovation and value creation, potentially benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates